Full Text
PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA

Abstract

Authors

JFS Logman MJ Taylor K Neumann L Kutikova KH Cerri BA Van Hout T Kühr

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×